Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

NCT03549689 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Withdrawn by drug manufacturer

Conditions

HIV/AIDS
HIV-1-infection
Osteopenia

Interventions

DRUG: Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)
DRUG: Current tenofovir alafenamide (TAF)-containing ART regimen

Sponsor

Philip Grant